MX2022009476A - Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. - Google Patents
Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.Info
- Publication number
- MX2022009476A MX2022009476A MX2022009476A MX2022009476A MX2022009476A MX 2022009476 A MX2022009476 A MX 2022009476A MX 2022009476 A MX2022009476 A MX 2022009476A MX 2022009476 A MX2022009476 A MX 2022009476A MX 2022009476 A MX2022009476 A MX 2022009476A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- binding fragments
- antl
- antibodies
- tmprss2 antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972338P | 2020-02-10 | 2020-02-10 | |
| US202063021016P | 2020-05-06 | 2020-05-06 | |
| US202063094199P | 2020-10-20 | 2020-10-20 | |
| PCT/US2021/017290 WO2021163076A1 (en) | 2020-02-10 | 2021-02-09 | ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009476A true MX2022009476A (es) | 2022-08-22 |
Family
ID=74798119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009476A MX2022009476A (es) | 2020-02-10 | 2021-02-09 | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11999799B2 (enExample) |
| EP (1) | EP4103619A1 (enExample) |
| JP (2) | JP7772702B2 (enExample) |
| KR (1) | KR20220140503A (enExample) |
| CN (1) | CN115427457A (enExample) |
| AU (1) | AU2021219671A1 (enExample) |
| CA (1) | CA3163164A1 (enExample) |
| IL (1) | IL294529A (enExample) |
| MX (1) | MX2022009476A (enExample) |
| WO (1) | WO2021163076A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021219671A1 (en) * | 2020-02-10 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Anti-Tmprss2 Antibodies and Antigen-Binding Fragments |
| US12133966B2 (en) | 2020-12-22 | 2024-11-05 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
| US20220193235A1 (en) * | 2020-12-22 | 2022-06-23 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion |
| US11806507B2 (en) | 2020-12-22 | 2023-11-07 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
| WO2023086989A1 (en) * | 2021-11-12 | 2023-05-19 | Adrx, Inc. | Transthyretin (ttr) monomer binding antibodies |
| JPWO2023199943A1 (enExample) * | 2022-04-12 | 2023-10-19 | ||
| CN116003611B (zh) * | 2022-08-17 | 2024-02-27 | 中南大学湘雅医院 | 抗tmprss2抗体及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| DE60138465D1 (de) | 2000-07-12 | 2009-06-04 | Agensys Inc | Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| WO2008127347A1 (en) | 2006-07-21 | 2008-10-23 | Diadexus, Inc. | Pro115 antibody compositions and methods of use |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US9212226B2 (en) | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| EP2838558A1 (en) | 2012-04-16 | 2015-02-25 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| EP3638698B1 (en) * | 2018-01-26 | 2021-03-03 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss2 antibodies and antigen-binding fragments |
| AU2021219671A1 (en) * | 2020-02-10 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Anti-Tmprss2 Antibodies and Antigen-Binding Fragments |
-
2021
- 2021-02-09 AU AU2021219671A patent/AU2021219671A1/en active Pending
- 2021-02-09 CN CN202180013863.0A patent/CN115427457A/zh active Pending
- 2021-02-09 JP JP2022547208A patent/JP7772702B2/ja active Active
- 2021-02-09 US US17/171,941 patent/US11999799B2/en active Active
- 2021-02-09 IL IL294529A patent/IL294529A/en unknown
- 2021-02-09 WO PCT/US2021/017290 patent/WO2021163076A1/en not_active Ceased
- 2021-02-09 MX MX2022009476A patent/MX2022009476A/es unknown
- 2021-02-09 CA CA3163164A patent/CA3163164A1/en active Pending
- 2021-02-09 KR KR1020227026885A patent/KR20220140503A/ko active Pending
- 2021-02-09 EP EP21708898.8A patent/EP4103619A1/en active Pending
-
2024
- 2024-04-22 US US18/642,721 patent/US20240343831A1/en active Pending
-
2025
- 2025-11-06 JP JP2025187155A patent/JP2026027362A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115427457A (zh) | 2022-12-02 |
| JP2023513124A (ja) | 2023-03-30 |
| IL294529A (en) | 2022-09-01 |
| US20210246226A1 (en) | 2021-08-12 |
| US11999799B2 (en) | 2024-06-04 |
| JP7772702B2 (ja) | 2025-11-18 |
| US20240343831A1 (en) | 2024-10-17 |
| KR20220140503A (ko) | 2022-10-18 |
| CA3163164A1 (en) | 2021-08-19 |
| WO2021163076A1 (en) | 2021-08-19 |
| JP2026027362A (ja) | 2026-02-18 |
| AU2021219671A1 (en) | 2022-07-14 |
| EP4103619A1 (en) | 2022-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006462A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| PH12021550793A1 (en) | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | |
| MX2022014598A (es) | Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno. | |
| MY209319A (en) | Compounds useful to treat influenza virus infections | |
| WO2018237148A8 (en) | Multispecific antibodies that target hiv gp120 and cd3 | |
| PH12018502673A1 (en) | Anti-zika virus antibodies and methods of use | |
| BR112024000744A2 (pt) | Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| EA202191736A1 (ru) | Комбинированная терапия hbv | |
| CR20220660A (es) | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 | |
| EA202090559A1 (ru) | Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение | |
| PH12021552903A1 (en) | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof | |
| WO2019106578A3 (en) | Polyomavirus neutralizing antibodies | |
| EA202192923A1 (ru) | Антитела и способы лечения инфекции, вызываемой вирусом гриппа а | |
| WO2021212049A3 (en) | Anti-sars-cov-2 monoclonal antibodies | |
| PH12020551051A1 (en) | Human antibodies to influenza hemagglutinin | |
| PH12023551390A1 (en) | Broadly neutralizing antibodies against influenza neuraminidase | |
| WO2019053613A3 (en) | Combination treatment for cancer | |
| MX2023005653A (es) | Anticuerpos contra los virus de la influenza a. | |
| MX2021014882A (es) | Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa. | |
| WO2019209974A3 (en) | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination | |
| WO2020053742A3 (en) | Anti-hla-hbv peptide antibodies | |
| PH12021550987A1 (en) | Anti-rabies monoclonal antibodies and cocktail thereof | |
| EA202190836A1 (ru) | Антитела и антигенсвязывающие фрагменты против гликопротеина шипов sars-cov-2 | |
| WO2023019174A3 (en) | Antibodies to sars-cov-2 |